Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer

Inclusion Criteria

• •1. ECOG. (Eastern Cooperative Oncology Group): 0-2
• •2. Histologic documentation of invasive duct or lobular adenocarcinoma of the breast
• •3. If neoadjuvant chemotherapy was NOT administered: pathologic T1-3, N1-2 following definitive surgery
• •4. If neoadjuvant chemotherapy was administered, pathology from the definitive surgery must confirm pathologic T1-3, N1-2 disease and also meet one of the following criteria:
• •Clinical T1-3, N1-2 or Pathologic confirmation of axillary nodal involvement at presentation (ie, before neoadjuvant therapy) based on any of the following: Positive fine-needle aspiration (FNA), Positive core needle biopsy.
• •5. Complete resection of known breast disease by one of the following surgeries Lumpectomy with axillary lymph node dissection with no more than 12 resected lymph nodes.
• •Mastectomy and axillary lymph node dissection with no more than 12 resected lymph nodes.
• •5- ER(estrogen-receptor), PR (progesterone-receptor), and HER2(human epidermal growth factor receptor 2) testing performed on the primary breast tumor; when applicable, testing must have been performed before receiving neoadjuvant chemotherapy.
• •6-Margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the pathologist.
• •7-The surgical wound should be completely healed without any signs of infection.
• •8-Interval between the last surgery for breast cancer or the completion of adjuvant chemotherapy and study enrollment must be ≤ 56 days (ie, a maximum of 8 weeks).
• •9-If adjuvant chemotherapy is received there should be at least 10 days gap between the last day of chemotherapy and the enrollment in the study to avoid skin toxicity.
• •10-Women of child-bearing potential must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment 11-Ability to understand and willingness to sign the consent form written in Arabic